昆药集团前三季度净利2.69亿元，同比下降39.42%

Core Viewpoint - Kunming Pharmaceutical Group reported a significant decline in both revenue and net profit for the first three quarters of 2025, indicating challenges in its business transformation and market conditions [1] Financial Performance - The company's revenue for the first three quarters reached 4.751 billion yuan, a year-on-year decrease of 18.08% [1] - The net profit attributable to shareholders was 269 million yuan, down 39.42% compared to the previous year [1] Reasons for Performance Decline - The decline in net profit is attributed to the company's ongoing transformation and channel reform, which has led to temporary pressure on sales [1] - Additional factors impacting performance include delays in the nationwide collection and expansion of traditional Chinese medicine, as well as the integration of retail pharmacy terminals [1]